PHILADELPHIA, Pennsylvania — A combination of dextromethorphan and quinidine (Nuedexta, Avanir Pharmaceuticals) significantly reduced symptoms of pseudobulbar affect (PBA) among patients with dementia ...
FDA grants Priority Review to AXS-05 (dextromethorphan/bupropion) for the treatment of agitation associated with Alzheimer disease.
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback